This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vertex Pharmaceuticals Incorporated
Drug Names(s): VX-702
Description: VX-702 inhibits p38 MAP kinase, which regulates agents involved in acute and chronic inflammation.
Deal Structure: In a collaboration with Kissei that began in 1997, Vertex is pioneering the discovery and development of novel p38 MAP kinase inhibitors. Under the agreement, Vertex holds the development and commercial rights in the United States and Europe for its p38 MAP kinase inhibitors. Kissei holds development and commercial rights in Japan and certain Asian countries for VX-702.
In 2007, Vertex concluded its agreement with Kissei for the development and commercialization of VX-702 in the Far East. Vertex retains worldwide development and commercial rights to VX-702.
Pink Sheet Vertex stops VX-745 trials
Additional information available to subscribers only: